Anavex Life Sciences Corp (AVXL)

[blu_1]

You're treating that EXPLORATORY Ph 2 trial like it was a pivotal Ph 3 trial whose primary endpoints were efficacy. That's not fair. Anavex was mainly trying to establish the safety record of the drug in Alz patients in that trial and try to establish the MTD. Efficacy was secondary. The efficacy measurables were so very strong, unprecedented in fact, that that is where a lot of the attention has been focused for this trial. Just b/c results are unexpected doesn't mean there's "something rotten in Denmark" with the trial, so to speak. It's not fair to jump to that conclusion unless there are facts to back it up